NYSE:AGN - Allergan Stock Price, Forecast & News

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

Allergan declared a quarterly dividend on Friday, October 25th. Shareholders of record on Wednesday, November 13th will be paid a dividend of $0.74 per share on Friday, December 13th. This represents a $2.96 dividend on an annualized basis and a yield of 1.55%. The ex-dividend date is Tuesday, November 12th. View Allergan's Dividend History.

Allergan announced that its board has authorized a stock buyback program on Tuesday, January 29th 2019, which allows the company to repurchase $2,000,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to repurchase up to 4.1% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company's board believes its shares are undervalued.

Allergan plc (NYSE:AGN) posted its quarterly earnings data on Tuesday, November, 5th. The company reported $4.25 EPS for the quarter, meeting the consensus estimate of $4.25. The company earned $4.03 billion during the quarter, compared to the consensus estimate of $3.88 billion. Allergan had a negative net margin of 58.50% and a positive return on equity of 9.08%. Allergan's revenue for the quarter was up 2.9% compared to the same quarter last year. During the same quarter last year, the firm posted $4.25 earnings per share. View Allergan's Earnings History.

Allergan is scheduled to release their next quarterly earnings announcement on Tuesday, February 4th 2020. View Earnings Estimates for Allergan.

Allergan issued an update on its FY19 earnings guidance on Tuesday, November, 5th. The company provided earnings per share (EPS) guidance of >$16.55 for the period, compared to the Thomson Reuters consensus EPS estimate of $16.74. The company issued revenue guidance of $15.6-15.8 billion, compared to the consensus revenue estimate of $15.58 billion.

20 analysts have issued 12-month target prices for Allergan's shares. Their forecasts range from $144.95 to $203.00. On average, they anticipate Allergan's stock price to reach $176.63 in the next year. This suggests that the stock has a possible downside of 7.3%. View Analyst Price Targets for Allergan.

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergan in the last year. There are currently 17 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Allergan.

Headlines about AGN stock have trended somewhat negative recently, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Allergan earned a news sentiment score of -1.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 7.0 out of 10, indicating that recent media coverage is likely to have an impact on the company's share price in the next few days. View News Stories for Allergan.

Allergan saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 14,580,000 shares, an increase of 19.2% from the December 15th total of 12,230,000 shares. Based on an average daily volume of 2,220,000 shares, the days-to-cover ratio is currently 6.6 days. Currently, 4.5% of the company's shares are sold short. View Allergan's Current Options Chain.

Some companies that are related to Allergan include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Horizon Therapeutics (HZNP), The Medicines (MDCO), Nektar Therapeutics (NKTR), Zogenix (ZGNX) and Pacira Biosciences (PCRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Allergan investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Micron Technology (MU), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Transocean (RIG) and United Rentals (URI).

Allergan's stock is owned by a number of of institutional and retail investors. Top institutional investors include Calamos Advisors LLC (0.11%), Metropolis Capital Ltd (0.06%), Vertex One Asset Management Inc. (0.05%), Advisors Capital Management LLC (0.04%), Nisa Investment Advisors LLC (0.03%) and Commerzbank Aktiengesellschaft FI (0.03%). Company insiders that own Allergan stock include Brent L Saunders, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado, Matthew M Walsh and William Meury. View Institutional Ownership Trends for Allergan.

AGN stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Commerzbank Aktiengesellschaft FI, United Services Automobile Association, Meag Munich Ergo Kapitalanlagegesellschaft MBH, Neville Rodie & Shaw Inc., State of Alaska Department of Revenue, Bowling Portfolio Management LLC and Tocqueville Asset Management L.P.. View Insider Buying and Selling for Allergan.

AGN stock was bought by a variety of institutional investors in the last quarter, including Syquant Capital Sas, Calamos Advisors LLC, Metropolis Capital Ltd, Vertex One Asset Management Inc., Moon Capital Management LLC, Modus Advisors LLC, Legacy Private Trust Co. and Wealthfront Advisers LLC. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado and Matthew M Walsh. View Insider Buying and Selling for Allergan.

Shares of AGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AGN stock can currently be purchased for approximately $190.55.

Allergan has a market capitalization of $62.55 billion and generates $15.79 billion in revenue each year. The company earns $-5,096,400,000.00 in net income (profit) each year or $16.69 on an earnings per share basis. Allergan employs 16,900 workers across the globe.View Additional Information About Allergan.

The official website for Allergan is http://www.allergan.com/.

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]